Metabolic reprogramming in CRC is also associated with the mutational status of Wnt/β-catenin pathway components and other genetic drivers, such as KRAS, BRAF, the tumor suppressor p53, EGFR and transforming growth factor-β (TGF-β), which promote tumor initiation and progression [29,30,31,32,33]. This evidence concerns the gene KRAS and neoplasm.